Trial Profile
TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary) ; Abiraterone acetate; Docetaxel; Enzalutamide
- Indications Adenocarcinoma; Carcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRITON3
- Sponsors Clovis Oncology [CEASED]; zr pharma
- 18 Mar 2024 Planned End Date changed from 1 Mar 2024 to 1 Dec 2024.
- 11 Aug 2023 Planned End Date changed from 1 Mar 2023 to 1 Mar 2024.
- 18 Feb 2023 Interim Results of overall survival (OS) and also report on efficacy of rucaparib compared individually with either DTX or ABI/ENZ, presented at the 2023 Genitourinary Cancers Symposium